Top 3 countries are UK, Switzerland and Greece. The top 25 stretch from Singapore, India and Japan to Israel and Ireland to name a few.
Brain if I'm not mistaken prior R&D costs, already expensed by Mannkind, will be allocated to COG which Sanofi will thus pay for and in turn will be additional profit for MNKD that Sanofi will not share in. I am assuming the allocation will be on a per unit basis. The question will be for what period of time that allocation will be made. Looking forward to some nice upside - and lots of happy Afrezza users. It's nice to invest in a stock that one believes in and for which one is genuinely happy to see users benefit so immensely.
Be careful what you wish for. Some on this board have noted that one star reviews of Afrezza were starting to appear on WebMD. Shorts have a lot to lose and some will stop at nothing. I noticed this morning that some have already started polluting a popular diabetes forum. They have no shame. Don't think they weren't beginning to post on Web MD as well. The advantage we have as longs have is that the drug speaks for itself and truth will win out, with or without WebMD.
If mnkd closes above $9 when opex expires, the purchaser(s) of the calls get(s) to keep the shares associated with those contracts. In this case there are 8520 contracts representing 852,000 shares.
I have a feeling that's a data error as OOG suggests - it's such an outlier. It should certainly be investigated by whomever is paying for and relying upon that data. If it's not an error then maybe there are more samples out there than we thought!
I've been thinking the same thing. There should also be a place for Yahoo Message Board characters, past and present.
I was struck by those. I checked the prior 7 weeks and they're all in the 50K range. Not sure what's going on. Hard to believe it's all Afrezza given that these are basals if I'm not mistaken. If it is Afrezza, yikes! I would still like to see the numbers for Humalog and Novolog for comparison.
Pediatric use will be the icing, decorations and candles on the cake. Can you imaging how dramatically the lives of diabetic children and their families will change.
oops haha. Been staring at the computer screen too long.
OOG you've been fantastic providing data. Do you have the numbers for Humalog and Novolog (RAA pens)? I believe those are the products Afrezza will most likely affect as users switch from pens to inhaler.
There is no reason for this not to happen imo. If you look at user experiences, those who have a rocky start with Afrezza are determined to get it right - and eventually do. The post by Laureen on Twitter only underscores that. Having difficulty with her insurance and currently paying out of pocket she says, "The Medical Directors aren't going to know what hit them. Now I'm just mad! I want Afrezza! I'm done with injections!" IMO - once Afrezza is tried there is no going back to needles. I can be patient. I can wait. Afrezza will revolutionize the delivery of prandial insulin. Watching this unfold will be a thing of beauty. JMHO.
You should feel more confident. I truly believe Afrezza will one day put insulin pens virtually out of business. The only ones using pens will be those who cannot inhale due to lung disease.